$509 Million is the total value of Johnson & Johnson Innovation - JJDC, Inc.'s 15 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals | $140,837,000 | +50.1% | 3,260,869 | 0.0% | 27.67% | -45.8% | |
| FATE | New | Fate Therapeutics, Inc. | $115,936,000 | – | 3,379,064 | +100.0% | 22.77% | – |
| LEGN | New | Legend Biotech Corporationsponsored ads | $69,338,000 | – | 1,629,173 | +100.0% | 13.62% | – |
| FUSN | New | Fusion Pharmaceuticals Inc. | $64,124,000 | – | 3,670,516 | +100.0% | 12.60% | – |
| PTGX | Protagonist Therapeutics Inc. | $43,253,000 | +150.1% | 2,449,183 | 0.0% | 8.50% | -9.7% | |
| MGTX | MeiraGTx Holdings plc | $36,290,000 | -6.8% | 2,898,550 | 0.0% | 7.13% | -66.4% | |
| PRVB | Provention Bio, Inc. | $15,873,000 | +53.4% | 1,124,973 | 0.0% | 3.12% | -44.6% | |
| PHGE | BiomX Inc. | $11,776,000 | -21.1% | 2,133,402 | 0.0% | 2.31% | -71.5% | |
| PHAS | PhaseBio Pharmaceuticals, Inc. | $7,392,000 | +39.0% | 1,607,044 | 0.0% | 1.45% | -49.8% | |
| ALDX | Aldeyra Therapeutics, Inc. | $2,480,000 | +68.8% | 594,834 | 0.0% | 0.49% | -39.1% | |
| CSLT | Castlight Health Inc.cl b | $673,000 | +14.7% | 811,295 | 0.0% | 0.13% | -58.6% | |
| CBIO | Catalyst Biosciences, Inc. | $393,000 | +34.1% | 66,951 | 0.0% | 0.08% | -51.6% | |
| GNCA | Genocea Biosciences, Inc. | $331,000 | +33.5% | 143,964 | 0.0% | 0.06% | -51.9% | |
| SENS | Senseonics Holdings, Inc. | $205,000 | -38.4% | 525,632 | 0.0% | 0.04% | -77.9% | |
| TCON | Tracon Pharmaceuticals, Inc. | $165,000 | +15.4% | 84,003 | 0.0% | 0.03% | -59.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | 7 | Q2 2021 | 74.6% |
| PROTAGONIST THERAPEUTICS INC. | 7 | Q2 2021 | 11.2% |
| BIOMX INC. | 7 | Q2 2021 | 8.1% |
| PHASEBIO PHARMACEUTICALS, INC. | 7 | Q2 2021 | 3.5% |
| ALDEYRA THERAPEUTICS, INC. | 7 | Q2 2021 | 1.2% |
| CASTLIGHT HEALTH INC. | 7 | Q2 2021 | 0.4% |
| SENSEONICS HOLDINGS, INC. | 7 | Q2 2021 | 0.2% |
| CATALYST BIOSCIENCES, INC. | 7 | Q2 2021 | 0.2% |
| TRACON PHARMACEUTICALS, INC. | 7 | Q2 2021 | 0.1% |
| MEIRAGTX HOLDINGS PLC | 6 | Q2 2021 | 21.2% |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-04-10 |
| 4 | 2024-03-06 |
| 13F-NT | 2024-02-14 |
| 3/A | 2024-02-02 |
| 4/A | 2024-02-02 |
| SC 13G | 2023-11-16 |
| 13F-NT | 2023-11-09 |
| 3 | 2023-09-18 |
| 3 | 2023-09-18 |
| 4 | 2023-09-18 |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.